1. Scrip
  2. >>Business

Zealand Investors DREAM On

 
• By Elizabeth Cairns

New academic data on obesity therapy dapiglutide are a prelude to a more significant readout.    

Double multiply exposure portrait of a dreamy cute woman meditating outdoors with eyes closed, combined with photograph of nature, sunrise or sunset, closeup. Migraine prevention
• Source: Shutterstock

Data on Zealand Pharma A/S’s obesity candidate dapiglutide are keenly awaited – but the results of the DREAM trial of the asset, released today, are not the right ones. Mean weight loss of just 4.3% was seen after three months’ treatment with low doses of dapiglutide, and Zealand’s shares slipped 3% to DKK582 on the Copenhagen exchange.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.